US-based contract research organisation (CRO) PPD has boosted its expertise in post-approval drug safety through a strategic alliance with World Health Information Science Consultants (WHISCON).

Headquartered in Wellesley, Massachusetts, WHISCON specialises in epidemiological studies and the interpretation of population health data. Under their agreement, PPD and WHISCON will jointly market their services to biomedical companies, insurers and government agencies worldwide.

The latter will draw on PPD’s experience with large drug studies, both pre- and post-approval, while the CRO will leverage WHISCON’s client relationships and global safety expertise in conducting epidemiology, risk-management, pharmacovigilance and observational studies.

“Epidemiology is playing a larger, more important role in understanding and evaluating risks related to drug safety,” noted Fred Eshelman, chief executive officer of PPD. “Our agreement with WHISCON will enhance our ability to help clients identify and manage the benefits and risks of their marketed products.”